SHINE granted production go-ahead

The U.S. Nuclear Regulatory Commission unanimously approved pursuing a construction permit for SHINE Medical Technologies, which has been working for four years to bring a production facility to Janesville that will produce molybdenum-99.

SHINE, of Monona, has developed a way to produce the radioactive substance, which decays into the isotope technetium-99m used in medical procedures, without using a nuclear reactor.

Construction on SHINE’s 57,000-square-foot plant will begin in 2017. It is expected to employ about 150 people.